Johnson & Johnson: Myelodysplastic Syndromes trials

The registry lists 21 Myelodysplastic Syndromes studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 6 have results posted.

Phase 1 6Phase 2 8Phase 3 3No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
• Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) TreatmentCompletedNCT03011034Phase 2Results posted
• An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic SyndromeCompletedNCT01751867Phase 3Results posted
• A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic SyndromeTerminatedNCT01513317Phase 2Results posted
• A Study of JNJ-30979754 (Decitabine) in Patients With Myelodysplastic SyndromeCompletedNCT00796003Phase 1Results posted
• An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)CompletedNCT00744757Phase 2Results posted
• A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for TransfusionTerminatedNCT00695396Phase 3Results posted
• A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT04609826Phase 1
• A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)WithdrawnNCT04264806Phase 2
• A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)CompletedNCT03915379Phase 1
• A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDSCompletedNCT03573310Phase 1
• An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01400633
• An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic SyndromesCompletedNCT01381809Phase 3
• A Study for Dacogen Treatment in Patients With Myelodysplastic SyndromeCompletedNCT01041846
• An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)No longer availableNCT01026376
• Survey on QUality of Life In myeloDisplasia (SQUID)CompletedNCT00967564
• A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic SyndromeTerminatedNCT00676728Phase 1
• A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)WithdrawnNCT00446602Phase 2
• SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.CompletedNCT00113893Phase 2
• Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT00050154Phase 2
• Combination Chemotherapy in Treating Patients With Myelodysplastic SyndromeStatus unknownNCT00003827Phase 2